Skip to main content
Log in

MicroRNA signatures in total peripheral blood of gallbladder cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that function as negative regulators of gene expression. Expression analysis of miRNAs can reflect the developmental lineage and differentiation state of the tumor. Thus, the miRNA profiles could play essential roles in gallbladder cancer (GBC). However, their role as novel biomarkers for the diagnosis of GBC is unclear yet. We assessed here for the first time whole-genome miRNA expression in peripheral blood samples of 40 GBC patients using microRNA microarray. We identified 11 miRNAs, which are significantly dysregulated in GBC patients in comparison to 40 healthy controls. Among these, the expression of let-7a, miR-21, miR-187, miR-143, miR-202, and miR-335 are in agreement with those measured by real-time PCR (p < 0.05). Furthermore, dysregulated miR-187, miR-143, and miR-202 demonstrate a significant correlation with clinicopathologic features (p < 0.05). Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–53.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.

    Article  CAS  PubMed  Google Scholar 

  4. Su M, Zhao X. Dignostic value of detection of CA19-9,CEA,AFP and CA125in gallbladder carcinoma patients. Med J PAPF. 2008;9(10):906–8.

    Google Scholar 

  5. Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.

    Article  CAS  PubMed  Google Scholar 

  6. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. Plos One. 2008;3(9):3138–45.

    Article  Google Scholar 

  7. Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67(1):129–39.

    Article  CAS  PubMed  Google Scholar 

  8. Chan SH, Wu CW, Li AF, et al. mir-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008;28(2):907–11.

    PubMed  Google Scholar 

  9. Michael MZ, O’Connor SM, Van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.

    CAS  PubMed  Google Scholar 

  10. Shell R, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancers. Proc Natl Acad Sci U S A. 2007;104(27):11400–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yu F, Yao H, Zhu P, et al. Let-6 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.

    Article  CAS  PubMed  Google Scholar 

  12. Szafranska AE, Davision TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;28(26):4442–52.

    Article  Google Scholar 

  13. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular cancinoma. J Clin Oncol. 2011;29(36):4781–8.

    Article  CAS  PubMed  Google Scholar 

  14. Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNa-187 through targeting disabled homolog-2. Oncogene. 2011;10(7):269–73.

    Google Scholar 

  15. Song T, Zhang X, Wang C, et al. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 2011;12(4):929–33.

    PubMed  Google Scholar 

  16. Huang HY, Cheng YY, Liao WC, et al. SoX4 transcriptionally regulates multipleSEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Plos One. 2012;7(12):48637–742.

    Article  Google Scholar 

  17. Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han population. Biochem Biophys Res Commun. 2013;430(2):529–34.

    Article  CAS  PubMed  Google Scholar 

  18. Hu Y, Ou Y, Wu K, et al. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol. 2012;33(6):1863–70.

    Article  CAS  Google Scholar 

  19. Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–9.

    Article  PubMed  Google Scholar 

  20. Ma Y, Zhang P, Wang F, et al. Mir-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank all the people and patients who had participated in this study.

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gangqiang Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, G., Pu, Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumor Biol. 36, 6985–6990 (2015). https://doi.org/10.1007/s13277-015-3412-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3412-4

Keywords

Navigation